AU2021398704A1 - Heterocyclic jak inhibitor - Google Patents

Heterocyclic jak inhibitor Download PDF

Info

Publication number
AU2021398704A1
AU2021398704A1 AU2021398704A AU2021398704A AU2021398704A1 AU 2021398704 A1 AU2021398704 A1 AU 2021398704A1 AU 2021398704 A AU2021398704 A AU 2021398704A AU 2021398704 A AU2021398704 A AU 2021398704A AU 2021398704 A1 AU2021398704 A1 AU 2021398704A1
Authority
AU
Australia
Prior art keywords
phenyl
compound
hydrogens
6alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021398704A
Other languages
English (en)
Inventor
Xiangyang Chen
Yucheng PANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of AU2021398704A1 publication Critical patent/AU2021398704A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021398704A 2020-12-18 2021-12-16 Heterocyclic jak inhibitor Pending AU2021398704A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011495497.0 2020-12-18
CN202011495497.0A CN114644633B (zh) 2020-12-18 2020-12-18 杂环类jak抑制剂
PCT/CN2021/138842 WO2022127869A1 (zh) 2020-12-18 2021-12-16 杂环类jak抑制剂

Publications (1)

Publication Number Publication Date
AU2021398704A1 true AU2021398704A1 (en) 2024-03-21

Family

ID=81990162

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021398704A Pending AU2021398704A1 (en) 2020-12-18 2021-12-16 Heterocyclic jak inhibitor

Country Status (7)

Country Link
US (1) US20240246984A1 (https=)
EP (1) EP4310088A4 (https=)
JP (1) JP2024522210A (https=)
CN (1) CN114644633B (https=)
AU (1) AU2021398704A1 (https=)
CA (1) CA3222404A1 (https=)
WO (1) WO2022127869A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306067A1 (en) * 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
EP2528918B1 (en) * 2010-01-29 2014-09-10 Nerviano Medical Sciences S.r.l. 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators
WO2016061751A1 (en) * 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
MX2020002869A (es) * 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.
WO2019074962A1 (en) * 2017-10-10 2019-04-18 Syros Pharmaceuticals, Inc. PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
JP7617030B2 (ja) * 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤

Also Published As

Publication number Publication date
US20240246984A1 (en) 2024-07-25
WO2022127869A1 (zh) 2022-06-23
EP4310088A1 (en) 2024-01-24
CA3222404A1 (en) 2022-06-23
CN114644633B (zh) 2026-02-03
JP2024522210A (ja) 2024-06-11
CN114644633A (zh) 2022-06-21
EP4310088A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
CN114751903B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
KR101792837B1 (ko) 키나아제 억제제로서 사용을 위한 이미다조피라진
TW202309027A (zh) 作為ｐａｒｐ抑制劑的化合物
TWI574691B (zh) Anti - tumor agents for intermittent administration of FGFR inhibitors
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CN113631557A (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
HK1223100A1 (zh) 杂环化合物
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
AU2007263017A1 (en) Pyridine and pyrazine derivatives as MNK kinase inhibitors
KR20150129010A (ko) Ido 억제제
TW200835481A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP2016537384A (ja) ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
KR102926602B1 (ko) 티로신 키나아제 2 활성을 조정하기 위한 헤테로사이클릭 화합물
US20230322789A1 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
AU2004283093A1 (en) Compounds and compositions as protein kinase inhibitors
CN114591351B (zh) 一种多环化合物及其制备方法和用途
CN116888126B (zh) 一种酪蛋白激酶抑制剂的化合物
AU2021398704A1 (en) Heterocyclic jak inhibitor
WO2025139240A1 (zh) Parp7抑制剂及其用途
IL279972A (en) Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
HK40091563A (zh) 嘧啶酮类化合物及其用途
HK40091563B (zh) 嘧啶酮类化合物及其用途
HK40077297B (zh) 氮杂-喹啉化合物及其用途

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 18 JUL 2023 TO 18 DEC 2023 IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 18 DEC 2023